Genistein increases estrogen receptor beta expression in prostate cancer via reducing its promoter methylation

J Steroid Biochem Mol Biol. 2015 Aug:152:62-75. doi: 10.1016/j.jsbmb.2015.04.018. Epub 2015 Apr 27.

Abstract

Genistein has protective effects against prostate cancer (PCa) but whether this protection involves an estrogen receptor (ER) β dependent mechanism has yet to be elucidated. ER-β has a tumor suppressor role in PCa and its levels decline with cancer progression which was linked to ER-β promoter hypermethylation. Genistein has been suggested to have demethylating activities in cancer. However, the ability of genistein to reverse ER-β promoter hypermethylation in PCa has not been studied. In addition, there are great discrepancies among studies that examined the effect of genistein on ER-β gene expression. Therefore, we sought to explore effects of genistein on ER-β promoter methylation as a mechanism of modulating ER-β expression using three PCa cell lines, LNCaP, LAPC-4 and PC-3. We also examined the role of ER-β in mediating the preventive action of genistein. Our data demonstrated that genistein at physiological ranges (0.5-10 μmol/L) reduced ER-β promoter methylation significantly with corresponding dose-dependent increases in ER-β expression in LNCaP and LAPC-4 but not in PC-3 cells, which could be attributed to the low basal levels of ER-β promoter methylation in PC-3 cell line. Genistein induced phosphorylation, nuclear translocation and transcriptional activity of ER-β in all three PCa cell lines. Inhibitory effects of genistein on LAPC-4 and PC-3 cell proliferation were diminished using a specific ER-β antagonist. In conclusion, genistein and ER-β act together to prevent PCa cell proliferation; genistein increases ER-β levels via reducing its promoter methylation and ER-β, in turn, mediates the preventive action of genistein.

Keywords: Estrogen receptor β; Genistein; Promoter methylation; Prostate cancer.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Active Transport, Cell Nucleus / drug effects
  • Base Sequence
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • DNA Methylation / drug effects*
  • Estrogen Receptor beta / antagonists & inhibitors
  • Estrogen Receptor beta / biosynthesis*
  • Estrogen Receptor beta / genetics
  • Genistein / pharmacology*
  • Humans
  • Male
  • Molecular Sequence Data
  • Phosphorylation / drug effects
  • Promoter Regions, Genetic / genetics*
  • Prostatic Neoplasms / drug therapy*
  • Protein Kinase Inhibitors / pharmacology
  • Pyrazoles / pharmacology
  • Pyrimidines / pharmacology
  • RNA Interference
  • RNA, Small Interfering
  • Transcription, Genetic / drug effects

Substances

  • 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol
  • Estrogen Receptor beta
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines
  • RNA, Small Interfering
  • Genistein